Department of Urology, The First Affiliated Hospital of Chongqing Medical University, chongqing, chongqing 400016 Recruiting
Chongqing, 400016, China
NCT Number: NCT06993779
Upper Tract Urothelial Carcinoma (UTUC), characterized by its anatomical complexity and often aggressive clinical behavior, presents substantial difficulties in accurate diagnosis and reliable prognostication. The stratification of postoperative survival utilizing radiomics features derived from imaging and characteristics from whole slide images could prove instrumental in guiding therapeutic decisions to enhance patient outcomes. In this research, our objective is to construct a deep learning-based prognostic-stratification system designed for the automated prediction of overall and cancer-specific survival in individuals diagnosed with UTUC.
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Chongqing, 400016, China
Upper Tract Urothelial Carcinoma (UTUC) can be challenging to accurately diagnose and its course difficult to predict, as the disease manifestations and aggressiveness can differ significantly among individuals. This research seeks to create an innovative system employing artificial intelligence to process patient data, encompassing images from diagnostic scans and surgical pathology slides. This system would then be capable of automatically forecasting a patient's overall survival and their specific likelihood of surviving UTUC. Such insights could empower clinicians to tailor more effective treatment strategies for each individual patient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.
Time frame: up to 10 years
the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off.
Time frame: up to 10 years
the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored
Mingzhao Xiao
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07155044
UC (Urothelial Cancer), UTUC
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07614594
Bladder Cancer (BC), Carcinoma
Zhengzhou, Henan, China
View Trial DetailsNCT06991868
Carcinoma, Female Urogenital Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06927128
NAC, UTUC
Shanghai, Shanghai Municipality, China
View Trial Details